{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:04:55Z","timestamp":1784297095533,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>More evidence for patterns of healthcare utilisation and associated costs among people receiving opioid agonist therapy (OAT) is needed. We investigated primary and secondary healthcare usage and costs among methadone and buprenorphine recipients in England.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study using the Clinical Practice Research Datalink GOLD and Aurum databases of patients who were prescribed OAT between 1 January 2007 and 31 July 2019. The cohort was linked to Hospital Episode Statistics admitted patient care, outpatient and emergency department data, neighbourhood\u2010 and practice\u2010level Index of Multiple Deprivation quintiles and mortality records. Negative binomial regression models were applied to estimate weighted rate ratios (wRR) of healthcare utilisation. Total and mean costs were calculated using Unit Costs of Health and Social Care and the National Healthcare Service Payment by Results National Tariffs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 12,639 patients observed over 39,016 person\u2010years, we found higher rate of hospital admissions (wRR 1.18; 1.08\u20131.28) among methadone compared with buprenorphine recipients. The commonest hospital discharge diagnoses among methadone patients were infectious diseases (19.2%), mental and behavioural disorders (17.0%) and drug\u2010related poisoning (16.5%); the three commonest among buprenorphine patients were mental and behavioural diseases (21.5%), endocrine (13.8%) and genitourinary system diseases (13.1%). Methadone patients had similar mean costs compared with buprenorphine patients (cost difference: \u00a3539.01; 432.11\u20131006.69).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>Differences in healthcare utilisation frequency for methadone versus buprenorphine recipients were observed. The differences in associated costs were mainly driven by hospital admissions. These findings offer valuable insights for optimising care strategies and resource allocation for OAT recipients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13933","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:12:23Z","timestamp":1724407943000},"page":"1845-1855","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-1288","authenticated-orcid":false,"given":"Eleni","family":"Domzaridou","sequence":"first","affiliation":[{"name":"National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester  Manchester UK"},{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Centre for Pharmacoepidemiology and Drug Safety University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Allen","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics University of Manchester  Manchester UK"},{"name":"Danish Centre for Health Economics University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Carr","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Centre for Pharmacoepidemiology and Drug Safety University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Millar","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Centre for Mental Health and Safety University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger T.","family":"Webb","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester  Manchester UK"},{"name":"Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, Centre for Mental Health and Safety University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Ashcroft","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester  Manchester UK"},{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Centre for Pharmacoepidemiology and Drug Safety University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"e_1_2_12_3_1","unstructured":"Office for National Statistics.Deaths related to drug poisoning in England and Wales: 2020 registrations.2021. Accessed 10 December 2023. Available from:https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2020"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.02.007"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00095-0"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.03.001"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14012"},{"key":"e_1_2_12_9_1","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group.Drug Misuse and Dependence: UK Guidelines on Clinical Management.2017. Accessed 10 April 2020. Available from:https:\/\/www.gov.uk\/government\/publications\/drug\u2010misuse\u2010and\u2010dependence\u2010uk\u2010guidelines\u2010on\u2010clinical\u2010management"},{"key":"e_1_2_12_10_1","unstructured":"Australian Government \u2013 Department of Health and age Care.National Guidelines for Medication\u2010Assisted Treatment of Opioid Dependence.2014. Accessed 10 February 2023. Available from:https:\/\/www.health.gov.au\/resources\/publications\/national\u2010guidelines\u2010for\u2010medication\u2010assisted\u2010treatment\u2010of\u2010opioid\u2010dependence"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-4358-1_12"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.027"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14892"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619854010"},{"key":"e_1_2_12_18_1","unstructured":"NHS Improvement.National cost collection for the NHS.2019. Accessed 31 May 2020. Available from:https:\/\/improvement.nhs.uk\/resources\/national-cost-collection\/"},{"key":"e_1_2_12_19_1","unstructured":"Unit Costs of Health and Social Care.PSSRU. Accessed 26 December 2022. Available from:https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/"},{"key":"e_1_2_12_20_1","unstructured":"GDP deflators at market prices and money GDP September 2021 (Quarterly National Accounts) \u2010 GOV.UK. Accessed 30 November 2022. Available from:https:\/\/www.gov.uk\/government\/statistics\/gdp\u2010deflators\u2010at\u2010market\u2010prices\u2010and\u2010money\u2010gdp\u2010september\u20102021\u2010quarterly\u2010national\u2010accounts"},{"key":"e_1_2_12_21_1","article-title":"Non\u2010fatal overdose risk during and after opioid agonist treatment: a primary care cohort study with linked hospitalisation and mortality records","volume":"22","author":"Domzaridou E","year":"2022","journal-title":"Lancet Reg Heal"},{"key":"e_1_2_12_22_1","unstructured":"Clinical Practice Research Datalink.Denominator data.2024. Accessed 20 May 2024. Available from:https:\/\/www.cprd.com\/denominator-data"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00620-6"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp16X687733"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16306"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15814"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.05.015"},{"issue":"8","key":"e_1_2_12_28_1","first-page":"S235","article-title":"Cost and utilization outcomes of opioid\u2010dependence treatments","volume":"17","author":"Baser O","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02539.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15911"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109494"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243317"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.03.018"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:58:28Z","timestamp":1730894308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/dar.13933"],"URL":"https:\/\/doi.org\/10.1111\/dar.13933","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"2024-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}